Skip to main content

Lantheus Holdings, Inc.

corporate_fare Company Profile

Lantheus Holdings, Inc.

LNTH·NASDAQ·Life Sciences·CIK 0001521036

We are a radiopharmaceutical-focused company that helps clinicians find, fight, and follow diseases to improve patient outcomes. Our products are categorized into Radiopharmaceutical Oncology, Precision Diagnostics, and Strategic Partnerships and Other Revenue. Our Radiopharmaceutical Oncology products assist healthcare professionals (HCPs) in finding, fighting, and following cancer. Our Precision Diagnostic products help HCPs find and follow diseases. Strategic Partnerships include biomarkers and digital solutions supporting partners' therapeutic development, out-licensing non-core assets, geographical asset optimization, and contract development and manufacturing organization (CDMO) revenue from Evergreen. Our commercial products are used by cardiologists, internal medicine physicians, neurologists, nuclear medicine physicians, oncologists, radiologists, sonographers, technologists, and urologists in various clinical settings. We believe our diagnostic products provide information for HCPs to better detect and characterize, or rule out, disease, potentially leading to better patient outcomes, reduced patient risk, and limited overall costs. We produce and market our products across the United States, primarily selling to hospitals, independent imaging centers, and government facilities. Outside the United States, we sell through direct distribution and third-party relationships in Europe, Canada, Australia, Asia-Pacific, Central America, and South America, and by licensing exclusive development and commercialization rights for certain products. We are headquartered in Massachusetts, with offices in New Jersey, Canada, Germany, Switzerland, Sweden, and the United Kingdom.

Lantheus Holdings, Inc. (NASDAQ:LNTH) is a publicly traded company in the Life Sciences sector. Wiseek has independently scored 37 items for LNTH at importance 7 or higher on its 1–10 market-impact scale. Its most recent item scored 7 or higher is dated 2026-11-12, rated 7/10. Across its 20 most recent items scored 7 or higher, the top rating is 10/10, with 7 rated 8 or above. Recent SEC coverage for LNTH spans SCHEDULE 13D/A, 10-Q, 8-K, DEFM14A.

Recent high-impact activity:

  • Lantheus Exits Perspective Therapeutics Stake, Selling 4M Shares
  • Lantheus to Divest CDMO Business and New Jersey Plant to PharmaLogic
  • Lantheus Beats Q3 Estimates With $1.68 Adjusted EPS, Revenue Up 1.5%
  • Lantheus Q3: Revenue $389.9M, $31M IPR&D Impairment, Cash Builds to $683.6M
  • Lantheus Posts $389.9M in Q3 Revenue, Edging Past Q2's $388.2M

Financial Snapshot

Fiscal year ended December 31, 2025
Revenue
$1.54B
Net Income
$233.56M
Diluted EPS
$3.41
Op. Cash Flow
$390.14M
Free Cash Flow
$354.05M
Gross Profit
$941.95M
Operating Income
$310.83M
Cash & Equivalents
$359.12M
Total Debt
$738K
Debt / Equity
0.00×
Net Margin
15.2%
Shares Outstanding
64.59M sh
Source: 10-K · filed 2026-02-26 · accession 0001193125-26-073498

Short Interest & Short Volume

3.23 days to cover

FINRA reported short interest of 3,640,835 shares in LNTH as of the October 30, 2026 settlement, a 0.2% increase from the prior period — about 3.2 days to cover at its recent average daily volume. On November 20, 2026, 40.7% of LNTH volume reported to FINRA trade-reporting facilities was marked short.

Short interest (bi-monthly positions)3,640,835 shares as of October 30, 2026
Change vs prior period▲ 0.2%
Days to cover3.23 at avg daily volume of 1,125,908
Daily short volume (FINRA facilities)40.7% of 290,659 shares on November 20, 2026
5-day average short volume23.9%

Daily short sale volume covers trades reported to FINRA trade-reporting facilities and is not the same as short interest (bi-monthly reported positions). Source: FINRA — FINRA is the owner and source of this short interest and short sale volume data; it may not be redistributed.

Browse all tickers starting with L →
$102.1
52-week range · as of 2026-11-12 $51.47 – $111.86
Market cap
$6.68B
Volume
1.1M (1.0× avg)
3-mo avg 1.1M
Live data · 2026-11-21 07:36 UTC · Market closed

show_chartPrice Chart

Loading chart...

feed LNTH - Latest Insights

LNTH
Nov 12, 2026, 4:34 PM EST
Filing Type: SCHEDULE 13D/A
Importance Score:
7
Price at Filing: $101.25
Real-time Price: $102.10 info
Change: +$0.850 (+0.84%) info
Market Cap: $6.677B info
LNTH
Nov 09, 2026, 4:12 PM EST
Source: Dow Jones Newswires
Importance Score:
7
Updated Nov 10, 6:07 AM ET — The PharmaLogic sale agreement includes a long-term supply deal under which PharmaLogic's Agilera unit will make lutetium Lu 177 dotatate f…
Price at Filing: $101.05
Real-time Price: $102.10 info
Change: +$1.05 (+1%) info
Market Cap: $6.677B info
LNTH
Nov 05, 2026, 11:24 AM EST
Source: Reuters
Importance Score:
7
Price at Filing: $100.97
Real-time Price: $102.10 info
Change: +$1.13 (+1%) info
Market Cap: $6.677B info
LNTH
Nov 05, 2026, 7:51 AM EST
Filing Type: 10-Q
Importance Score:
7
Price at Filing: $100.61
Real-time Price: $102.10 info
Change: +$1.49 (+1%) info
Market Cap: $6.677B info
LNTH
Nov 05, 2026, 7:00 AM EST
Source: Dow Jones Newswires
Importance Score:
7
Price at Filing: $100.61
Real-time Price: $102.10 info
Change: +$1.49 (+1%) info
Market Cap: $6.677B info
LNTH
Oct 22, 2026, 7:30 AM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $100.24
Real-time Price: $102.10 info
Change: +$1.86 (+2%) info
Market Cap: $6.677B info
LNTH
Oct 15, 2026, 7:47 AM EDT
Source: Reuters
Importance Score:
7
Price at Filing: $100.00
Real-time Price: $102.10 info
Change: +$2.10 (+2%) info
Market Cap: $6.677B info
LNTH
Oct 14, 2026, 4:30 PM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $100.00
Real-time Price: $102.10 info
Change: +$2.10 (+2%) info
Market Cap: $6.677B info
LNTH
Oct 02, 2026, 5:00 PM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $99.96
Real-time Price: $102.10 info
Change: +$2.14 (+2%) info
Market Cap: $6.677B info
LNTH
Sep 30, 2026, 8:30 AM EDT
Source: GlobeNewswire
Importance Score:
7
Price at Filing: $99.60
Real-time Price: $102.10 info
Change: +$2.50 (+3%) info
Market Cap: $6.677B info
LNTH
Sep 22, 2026, 8:00 AM EDT
Source: GlobeNewswire
Importance Score:
8
Price at Filing: $99.60
Real-time Price: $102.10 info
Change: +$2.50 (+3%) info
Market Cap: $6.677B info
LNTH
Sep 21, 2026, 4:05 PM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $100.28
Real-time Price: $102.10 info
Change: +$1.82 (+2%) info
Market Cap: $6.677B info
LNTH
Sep 08, 2026, 6:03 AM EDT
Filing Type: DEFM14A
Importance Score:
9
Price at Filing: $100.97
Real-time Price: $102.10 info
Change: +$1.13 (+1%) info
Market Cap: $6.677B info
LNTH
Aug 26, 2026, 7:20 AM EDT
Filing Type: PREM14A
Importance Score:
9
Price at Filing: $100.80
Real-time Price: $102.10 info
Change: +$1.30 (+1%) info
Market Cap: $6.677B info
LNTH
Aug 14, 2026, 8:03 AM EDT
Source: Reuters
Importance Score:
8
Price at Filing: $101.00
Real-time Price: $102.10 info
Change: +$1.10 (+1%) info
Market Cap: $6.677B info
LNTH
Aug 10, 2026, 7:37 AM EDT
Source: Wiseek News
Importance Score:
7
Price at Filing: $100.50
Real-time Price: $102.10 info
Change: +$1.60 (+2%) info
Market Cap: $6.677B info
LNTH
Aug 06, 2026, 8:01 AM EDT
Filing Type: 10-Q
Importance Score:
8
Price at Filing: $101.50
Real-time Price: $102.10 info
Change: +$0.600 (+0.59%) info
Market Cap: $6.677B info
LNTH
Aug 06, 2026, 7:45 AM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $101.50
Real-time Price: $102.10 info
Change: +$0.600 (+0.59%) info
Market Cap: $6.677B info
LNTH
Aug 06, 2026, 7:15 AM EDT
Source: Reuters
Importance Score:
7
Price at Filing: $101.50
Real-time Price: $102.10 info
Change: +$0.600 (+0.59%) info
Market Cap: $6.677B info
LNTH
Aug 03, 2026, 9:00 PM EDT
Filing Type: 8-K
Importance Score:
10
Price at Filing: $101.95
Real-time Price: $102.10 info
Change: +$0.150 (+0.15%) info
Market Cap: $6.677B info
Research tools: Filing Impact Index Dilution Tracker Split Calendar Open Datasets